JANX vs. INDV, MOR, EVO, SMMT, MLTX, CORT, ACAD, MRUS, VERA, and RYTM
Should you be buying Janux Therapeutics stock or one of its competitors? The main competitors of Janux Therapeutics include Indivior (INDV), MorphoSys (MOR), Evotec (EVO), Summit Therapeutics (SMMT), MoonLake Immunotherapeutics (MLTX), Corcept Therapeutics (CORT), ACADIA Pharmaceuticals (ACAD), Merus (MRUS), Vera Therapeutics (VERA), and Rhythm Pharmaceuticals (RYTM). These companies are all part of the "pharmaceutical preparations" industry.
Janux Therapeutics (NASDAQ:JANX) and Indivior (NASDAQ:INDV) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, community ranking, risk, earnings and media sentiment.
Janux Therapeutics has a beta of 4.18, meaning that its share price is 318% more volatile than the S&P 500. Comparatively, Indivior has a beta of 0.46, meaning that its share price is 54% less volatile than the S&P 500.
Indivior has a net margin of 0.18% compared to Janux Therapeutics' net margin of -721.18%. Indivior's return on equity of 538.18% beat Janux Therapeutics' return on equity.
Indivior has higher revenue and earnings than Janux Therapeutics. Indivior is trading at a lower price-to-earnings ratio than Janux Therapeutics, indicating that it is currently the more affordable of the two stocks.
Janux Therapeutics received 18 more outperform votes than Indivior when rated by MarketBeat users. However, 100.00% of users gave Indivior an outperform vote while only 58.82% of users gave Janux Therapeutics an outperform vote.
Janux Therapeutics presently has a consensus target price of $61.33, suggesting a potential upside of 26.15%. Indivior has a consensus target price of $36.00, suggesting a potential upside of 90.88%. Given Indivior's higher probable upside, analysts clearly believe Indivior is more favorable than Janux Therapeutics.
75.4% of Janux Therapeutics shares are owned by institutional investors. Comparatively, 60.3% of Indivior shares are owned by institutional investors. 35.4% of Janux Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
In the previous week, Janux Therapeutics had 2 more articles in the media than Indivior. MarketBeat recorded 3 mentions for Janux Therapeutics and 1 mentions for Indivior. Indivior's average media sentiment score of 0.78 beat Janux Therapeutics' score of 0.38 indicating that Indivior is being referred to more favorably in the news media.
Summary
Indivior beats Janux Therapeutics on 9 of the 17 factors compared between the two stocks.
Get Janux Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for JANX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding JANX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Janux Therapeutics Competitors List
Related Companies and Tools
